1
Eli Lilly and Company, Indianapolis, IN, USA, 2 Daiichi Sankyo, Inc., Parsippany, NJ, USA OBJECTIVES: To characterize ACS-PCI patients including the index hospitalization charges and length-of-stay (LOS) in a US health benefit plan. METHODS: The data source was Invision from i3, a division of UnitedHealth. ACS diagnoses were from ICD-9 codes 410.xx or 411.1. PCI procedure codes were 00. 66, 36.0X, 92973, 92975, 92978 −92982, 92984, 92995/6 , and G0290/1. The definition of ACS-PCI was PCI within 30 days of an ACS diagnosis. The diagnosis related group (DRG) codes (555, 556, 557, 558) and corresponding descriptions are from Version 23 and 24. Charges are in 2006 dollars. Continuous enrollment was required during the year 2006 and a minimum of 1 year before the index PCI. Patients with a history of transient ischemic attack or stroke were excluded. A clopidogrel claim was required within 60 days after hospitalization. RESULTS: Of the 6687 patients who had ACS-PCI and met the other inclusion criteria, 5174 (77.4%) were male, 5587 (83.6%) were under 65 years of age, and 1777 (26.6%) had a diabetes diagnosis. Drug-eluting stents (DES, n = 5541, 82.9%) were frequently used. The 3249 patients with DRG557, DES with a major cardiovascular diagnosis (CVDx), had a mean length of stay (LOS) of 2.9 days and mean charges of $54,271. The 2292 patients with DRG558, DES without major CVDx, had a mean LOS of 1.7 days and mean charges of $44,230. The corresponding cohorts receiving bare metal stents (BMS) with (DRG555, n = 602) and without (DRG556, n = 187) major CVDx had mean LOS of 2.9 and 1.8 days with mean hospital charges of $46,106 and $34,109 respectively. CONCLUSIONS: For ACS patients who underwent PCI, the mean charge was approximately $10,000 higher and the mean LOS was 1 day longer for the cohort with major CVDx, as per the DRG definition, compared to the cohort without major CVDx.
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MANAGEMENT OF ACUTE ISCHEMIC STROKE IN THE USA
Rouleau A 1 , Mouchet J 2 , Guilhaume C 1 , Milea D 1 , Maier W 3 1 Lundbeck SAS, Issy-les-Moulineaux, France, 2 MAPI Research Trust, Lyon, France, 3 MAPI-EPI, London, UK OBJECTIVES: Describe the management of ischemic stroke patients in acute phase and its impact on long-term stroke evolution in the USA. METHODS: Medline was searched from 1999 to date and ISPOR Digest was screened to identify stroke cohorts and registries containing data for the last ten years in the USA. A ranking process was implemented to identify and select the relevant references. RESULTS: A total of 461 references were retrieved. The selection process led to the identification of 78 publications (42 cohorts, 9 registries and 5 database studies) of which 41 focused on ischemic stroke only. Sixty-nine percent of the studies were hospital-based and 31% population-based. The studies aimed to characterise determinants that impact acute phase management and outcomes, in particular demographic and clinical factors. Hospital settings and associated care facilities were studied in order to improve disease management by identifying specific barriers to the administration of the only available thrombolytic treatment (recombinant tissue-type plasminogen activator, rt PA) in acute phase. Of these studies, many were not applicable to all ischemic stroke patients. Studies documenting the use of rt-PA showed that: less than 25% of patients arrived within 3 hours (i.e. time eligibility criteria for therapy) and 38.3% to 48.2% of them were excluded because of medical contraindications. Consequently, 10.9% to 14% of ischemic patients should have been given rt PA, but in natural settings, only 3.2% actually received it. In addition, long-term evolution of ischemic patients (mortality, stroke recurrence and cardiac events) was documented in several studies, but the evolution of disability after more than 3-months was not assessed. CONCLUSIONS: As shown above, general information about management of ischemic stroke in acute phase is lacking. New cohort or registry studies aiming to better describe patterns of ischemic stroke care that influence short and long-term clinical and associated economic outcomes need to be developed. (2006) fee-for-service, Medicare Part D and low-income subsidy (LIS) or non-LIS eligibility. Study outcomes included any drug use, adherence (percent days covered (PDC) ≥0.8), and discontinuation (≥30-day continuous gap). The study employed a quasi-experimental design using a pre-(prior to donut hole) and post-(during donut hole) periods comparing three patient groups (non-LIS: without coverage, generic only coverage, and brand / generic coverage during the gap) with a contemporaneous control group (LIS: no coverage gap). A difference-in-difference approach was used with multiple regressions controlling for demographic characteristics, Medicare entitlement status, area-level information, and clinical risk. RESULTS: The donut hole was associated with statistically significant decreases in any drug use and PDC adherence, along with an increase in the likelihood of a discontinuation for both lipid lowering and antihypertensive drugs. The magnitude of impact was largest among patients without donut-hole drug coverage: 1.1% to 4.1% drop in probability of drug use; 4.4% to 12.1% decrease in adherence; and 4.5% to 12.5% increase in discontinuations (p < 0.01 for all). Impact was smallest among patients with both generic/brand drug coverage relative to the LIS controls. The donut hole had no impact on probability of using symptomatic drugs (anti-ulcer agents, antidepressants, and pain-killers). CONCLUSIONS: The donut hole was associated with statistically significant but modest drops in the use of drugs for asymptomatic conditions, but had no impact on drugs for symptomatic conditions. Patients with no coverage during the donut hole experienced the largest impacts.
PCV121 THE IMPACT OF PART D ON PREVIOUSLY UNINSURED MEDICARE BENEFICIARIES WITH HYPERTENSION
Shoemaker JS University of Maryland Baltimore, Baltimore, MD, USA OBJECTIVES: To assess the effect of Medicare Part D enrollment on changes in antihypertensive drug utilization for a nationally-representative sample of Medicare beneficiaries without prior prescription coverage. Part D enrollees have characteristics associated with above average drug use. To date, no nationally-representative studies have evaluated the impact of Part D on drug utilization controlling for these selection effects. Panel data methods address these biases in studying treatment for a chronic condition for which drug therapy can promote long term benefits. METHODS: Longitudinal Medicare Current Beneficiary Survey (MCBS) data from the year before and after implementation of Part D. Unit of observation is the person-trimester, defined as the interval between subsequent MCBS survey dates. Primary sample of beneficiaries reporting a diagnosis of hypertension without drug coverage in 2005 and completed all 6 survey rounds in 2005 and 2006 (N = 3039 person trimesters). Secondary control sample of beneficiaries continuously enrolled in employer-sponsored insurance (ESI) as a sensitivity analysis (N = 5,608 person trimesters). Fixed effects and difference-in-difference (DID) multivariate methods compare changes in drug fills over six 4-month periods for beneficiaries who enrolled in Part D and those who did not. RESULTS: A total of 67% of the primary sample enrolled in Part D. Descriptive trend analysis shows a monotonic increase in mean antihypertensive fills by trimester ranging from 4.0 to 7.1 for Part D enrollees, compared to a range from 2.7 to 4.4 for non-enrollees. In adjusted DID comparisons, Part D enrollees experienced 1.79 additional antihypertensive fills per trimester relative to non-enrollees (p < 0.05). Fixed effects methods suggest that Part D enrollees filled an additional 1.08 prescriptions per trimester (p < 0.05). Sensitivity analysis show comparable results. CONCLU-SIONS: Enrollment in Part D increased drug utilization for a class of drugs known to
